Prenetics
A Hong Kong-headquartered health sciences company focused on disease prevention, early detection and treatment, particularly in cancer care.
Last updated August 31, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Prenetics is a Hong Kong-headquartered health sciences company whose activities center on disease prevention, early detection and treatment. Its work has particularly emphasized cancer screening, genomic and molecular testing, consumer health, and wellness. The company operates through a portfolio of businesses and subsidiary brands, including CircleDNA, Insighta and IM8, and has maintained a presence in the United States in addition to its Hong Kong base. The company’s consumer and diagnostic activities developed around the use of DNA and other molecular information to identify health risks before symptoms become apparent. CircleDNA, one of Prenetics’ principal brands, has positioned genetic testing primarily as a preventive-health service rather than as a genealogy product. Its offerings have included a rapid DNA-based colorectal-cancer screening product, introduced in 2016, and a range of at-home tests launched for retail distribution in Asian markets in 2019. These products reflect Prenetics’ effort to make testing more accessible outside conventional hospitals and laboratories, although the clinical utility, regulatory status and availability of individual tests depend on the market in which they are offered. Prenetics also expanded toward large-scale disease detection through Insighta, a joint venture announced in 2023 with The Chinese University of Hong Kong and molecular biologist Dennis Lo. The planned project was described as a US$200 million initiative intended to develop DNA-based tests for several major diseases and cancers. Its proposed early-detection cancer test, Presight, was expected to enter clinical trials in 2024; the available reference material states that no such trials had been publicly announced as of 2025. This makes Insighta an important part of Prenetics’ research and development strategy, but also an area in which commercial and clinical outcomes remained unconfirmed. During the COVID-19 pandemic, Prenetics became a significant testing-services provider. It was one of three companies selected to support COVID-19 testing for the Hong Kong government. Its United Kingdom operation also supplied testing for the Premier League as English football prepared to resume competition under the pandemic-era Project Restart arrangements. Prenetics established temporary testing sites and used former footballer Rio Ferdinand in communications intended to reassure players about the safety of the testing and restart program. After becoming a public company, Prenetics faced the profitability and share-price pressures common among recently listed growth businesses. The company became the first Hong Kong-based unicorn to list on Nasdaq after completing a merger with the special-purpose acquisition company Artisan Acquisition Corp. It subsequently struggled to generate a profit. In October 2023, Prenetics announced a one-for-fifteen reverse stock split designed to help restore compliance with Nasdaq’s minimum US$1 share-price requirement. Prenetics continued broadening its business beyond diagnostics. In 2024 it partnered with investor and former footballer David Beckham to establish IM8, a consumer wellness brand. In 2026, the company announced podcast host and author Jay Shetty as IM8’s global ambassador. The portfolio therefore spans laboratory and genetic testing, early cancer detection research, pandemic testing services and consumer wellness. Its overall positioning is that of a technology-enabled health company seeking to connect prevention, diagnostics and lifestyle products, while its long-term performance depends on regulatory acceptance, clinical validation, commercialization and the ability to reach profitability.
History
Prenetics developed as a Hong Kong health sciences company built around the use of genetic and molecular information in preventive healthcare. Rather than concentrating solely on genealogy, its consumer-facing activities emphasized health-risk assessment and the possibility of identifying disease earlier. This approach was expressed through CircleDNA, a subsidiary brand associated with DNA-based preventive testing. CircleDNA introduced a rapid DNA-based colorectal-cancer screening product in 2016. The product represented an effort to move genetic and molecular testing toward earlier intervention and broader consumer access. In 2019, the brand expanded its commercial reach by launching at-home tests intended for sale through retailers in Asian markets. These products placed Prenetics within the growing direct-to-consumer testing sector, where convenience and accessibility are balanced against questions concerning medical oversight, test validation, regulation and the interpretation of results. The company’s role expanded substantially during the COVID-19 pandemic. Prenetics was selected as one of three companies providing testing support to the Hong Kong government. Its United Kingdom operation also supplied COVID-19 testing for the Premier League during the effort to restart professional football. The program, commonly associated with Project Restart, required regular testing and safety procedures. Prenetics opened pop-up testing sites, and former FIFA player Rio Ferdinand was hired for communications intended to reassure footballers about the safety of the restart plan. The pandemic gave the company a high-profile operational role in large-scale testing, while also connecting its diagnostic capabilities with public-sector and sports-industry requirements. Prenetics later pursued a more ambitious molecular-diagnostics strategy through Insighta. In 2023, the company announced a US$200 million joint venture with The Chinese University of Hong Kong and molecular biologist Dennis Lo. Insighta was intended to develop DNA-based tests for several major diseases and cancers. Its proposed early-detection cancer test, Presight, was expected to begin clinical trials in 2024. The available reference material indicates that no clinical trials had been announced publicly as of 2025, leaving the program’s clinical progress and commercial timetable uncertain. The company’s route to public markets involved a merger with Artisan Acquisition Corp., a special-purpose acquisition company. The transaction made Prenetics the first Hong Kong-based unicorn to list on Nasdaq. Public-market status increased the company’s visibility and provided a platform for financing its expansion, but it also exposed Prenetics to the pressure of investor expectations and listing requirements. Following the listing, the company struggled to turn a profit. In October 2023, it announced a one-for-fifteen reverse stock split intended to help its share price regain compliance with Nasdaq’s requirement that listed shares trade at or above US$1. Prenetics subsequently broadened its commercial scope into wellness. In 2024, it partnered with investor and former footballer David Beckham to form IM8, a consumer wellness brand. The venture extended the group’s identity beyond laboratory testing and cancer-detection research into products and services associated with everyday health and lifestyle. In 2026, Prenetics announced podcast host and author Jay Shetty as IM8’s global ambassador, adding a prominent media and personal-development figure to the brand’s marketing platform. As represented by its portfolio of CircleDNA, Insighta and IM8, Prenetics combines consumer diagnostics, research-oriented early detection, pandemic testing experience and wellness products. The group’s history is consequently marked by movement between regulated healthcare, technology-enabled consumer services and brand-led wellness. Its future development depends on the validation and approval of diagnostic technologies, successful commercialization, market access, operational execution and progress toward sustainable profitability.
- 2026
Jay Shetty is announced as IM8 global ambassador
[1]Prenetics announced Jay Shetty as global ambassador for IM8.
- 2024
IM8 wellness brand is formed with David Beckham
[1]Prenetics partnered with David Beckham to create IM8, a consumer wellness brand.
- 2023
Insighta joint venture is announced
[1]Prenetics announced a US$200 million joint venture with The Chinese University of Hong Kong and Dennis Lo to develop DNA tests for major diseases and cancers.
- 2023
Reverse stock split announced
[1]Prenetics announced a one-for-fifteen reverse stock split to address Nasdaq’s minimum share-price requirement.
- 2019
CircleDNA expands into retail-distributed at-home testing
[1]CircleDNA launched a range of at-home tests intended for sale through retailers in Asian markets.
- 2016
CircleDNA launches a rapid DNA-based colorectal-cancer screening product
[1]CircleDNA introduced a rapid DNA-based product aimed at colorectal-cancer screening and preventive health.
Prenetics supports COVID-19 testing in Hong Kong and the United Kingdom
[1]The company was selected to provide testing support for the Hong Kong government and supplied testing for the Premier League’s pandemic-era restart effort in the United Kingdom.
Prenetics lists on Nasdaq through a SPAC merger
[1]A merger with Artisan Acquisition Corp. made Prenetics the first Hong Kong-based unicorn to list on Nasdaq.
Products and positioning
A technology-enabled health sciences group focused on prevention, early disease detection, cancer diagnostics and consumer wellness.
Genetic testing and preventive health · 2016
CircleDNA
CircleDNA is a Prenetics subsidiary brand focused on consumer-oriented DNA testing for health prevention rather than genealogy. Its activities have included a rapid DNA-based colorectal-cancer screening product introduced in 2016 and at-home tests made available through retail channels in Asian markets from 2019. The precise availability, regulatory status and clinical claims of its products vary by jurisdiction.
Molecular diagnostics research · 2023
Insighta
Insighta is a planned disease-detection venture established by Prenetics with The Chinese University of Hong Kong and molecular biologist Dennis Lo. Announced in 2023 with a stated investment of US$200 million, it is intended to develop DNA-based tests for several major diseases and cancers. The venture’s proposed early-detection cancer test is called Presight. Public clinical-trial progress remained unconfirmed in the available material as of 2025.
Early cancer detection
Presight
Presight is the proposed early-detection cancer test associated with Insighta. It was expected to enter clinical trials in 2024, but the available reference material states that no clinical trials had been publicly announced as of 2025. Its final regulatory pathway, commercial launch status and performance characteristics therefore remain unclear.
Consumer wellness · 2024
IM8
IM8 is a consumer wellness brand formed by Prenetics in partnership with David Beckham in 2024. It represents the company’s expansion from diagnostics and disease detection into lifestyle-oriented health products. Available reference material does not specify the complete product range or the markets in which each offering is sold.
Marketing campaigns
- 2024IM8 launch partnership with David Beckham
International
Prenetics partnered with David Beckham to launch the IM8 consumer wellness brand, using Beckham’s public profile to support the group’s move into lifestyle health.
Outcome. IM8 became one of Prenetics’ subsidiary brands; detailed sales and market-performance results are not provided in the available material.
- Project Restart Premier League testing program
United Kingdom
Prenetics’ United Kingdom operation provided COVID-19 testing for the Premier League as football prepared to resume during the pandemic. The company also used pop-up testing sites, while Rio Ferdinand participated in communications intended to reassure players about the safety of the restart plan.
Outcome. The testing program supported the planned resumption of professional football, although the available material does not provide a quantified commercial or operational outcome.
Brand decisions
2024
Expansion into consumer wellness through IM8Product launchBackground
Prenetics broadened its portfolio beyond diagnostics and early-detection research into consumer lifestyle and wellness.
Action taken
The company partnered with David Beckham to form the IM8 wellness brand.
Aftermath
IM8 became a subsidiary brand within Prenetics’ portfolio. The available material does not report detailed financial results or the full product range.
2023
One-for-fifteen reverse stock splitOtherBackground
After listing on Nasdaq, Prenetics struggled to turn a profit and faced pressure from the exchange’s minimum US$1 share-price requirement.
Action taken
The company announced a reverse stock split under which fifteen existing shares would be consolidated into one share.
Aftermath
The measure was intended to restore listing compliance. The available material does not establish whether it produced a sustained improvement in the company’s operating performance.
2023
Formation of the Insighta disease-detection ventureStrategyBackground
Prenetics sought to extend its capabilities from consumer testing and pandemic diagnostics into large-scale molecular detection of cancer and other diseases.
Action taken
It announced a US$200 million joint venture with The Chinese University of Hong Kong and Dennis Lo to develop DNA tests for several major diseases and cancers.
Aftermath
The proposed Presight cancer test was expected to begin clinical trials in 2024, but no clinical trials had been publicly announced by 2025 according to the available reference material.
Planned joint-venture investment. US$200 million (Announced in 2023)
Recent events
Reported
Prenetics and Artisan announce merger agreement[2]
Prenetics and Artisan Acquisition Corp. announced that they had signed a merger agreement. The transaction valued Prenetics at an enterprise value of $1.25 billion and a combined equity value of about $1.7 billion; completion was expected in the fourth quarter of 2021 or the first quarter of 2022.
Reported
Prenetics signs molecular diagnostics collaboration agreements with Oxford University and OSCAR[3]
Prenetics, Oxford University and Oxford Suzhou Centre for Advanced Research signed multi-million-dollar collaboration agreements to further develop OxLAMP technology for molecular testing. The three-year collaboration also includes a Prenetics Innovation Technology Centre for advanced molecular diagnostics based in Oxford Suzhou.
- Unconfirmed
Reported
Prenetics and DNAFit acquire Oxsed[4]
Prenetics and its wholly owned UK entity DNAFit acquired Oxsed and exclusive global rights to its technology. Oxsed developed a rapid COVID-19 testing platform based on Oxford University research.
Reported
Dorsett partners with Prenetics to offer COVID-19 testing[5]
Dorsett Hospitality International partnered with Prenetics to offer Hong Kong residents, associates, and hotel guests access to COVID-19 tests through its hotels.
Sources6 sources
- 1Preneticsen.wikipedia.org
- 2Prenetics与Artisan宣布合并协议prnasia.com
- 3Prenetics 与牛津大学及 OSCAR 签署分子诊断合作协议prnewswire.com
- 4Prenetics 与 DNAFit 收购 Oxsedprnewswire.com
- 5帝盛与Prenetics合作提供新冠检测finanznachrichten.de
- 6Dorsett Hospitality Intl Partners With Prenetics To Provide Government-Recognised Covid-19 Testingscoop.co.nz
Cite this profile: Cite the canonical profile. /brand-wiki/prenetics · Editorial policy · How profiles are compiled